MedTrace Logo

Adjunct Dexmedetomidine (Precedex®) Therapy Impact on Sedative and Analgesic Requirement

NCT00852046 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2011-10-06

No results posted yet for this study

Summary

Assess impact of increasing dose of dexmedetomidine on total daily dose of fentanyl and propofol while maintaining sedation in a mechanically ventilated patient in a general medical intensive care unit.

Conditions

  • Sedation
  • Analgesia

Interventions

DRUG

Dexmedetomidine

IV solution, 0.2 mcg/kg/hr or 0.6 mcg/kg/hr for a max of 5 days

Sponsors & Collaborators

  • Avera McKennan Hospital & University Health Center

    lead OTHER

Principal Investigators

  • John A Kappes, Pharm.D. · Avera McKennan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2009-03-31
Completion
2009-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00852046 on ClinicalTrials.gov